c-MET Antibody Guideline: Preparation, Dilution and Applications

c-MET Antibody Overview

There are 24 c-MET antibodies which are validated in multiple tissues with various applications, including WB, ELISA, FCM, ELISA(Cap). There are 1 c-MET antibody for WB, 15 c-MET antibody for ELISA, 8 c-MET antibody for FCM, 1 c-MET antibody for ELISA(Cap). Among all these c-MET antibodies, there are 8 anti-c-MET rabbit polyclonal antibodies , 2 anti-c-MET mouse monoclonal antibodies , 14 anti-c-MET rabbit monoclonal antibodies . All the c-MET anbodies are produced in house and all are in stock. c-MET antibody customerized service is available.

c-MET Antibody ELISA

c-MET antibody ELISA preparation

This antibody was produced from a hybridoma resulting from the fusion of a mouse myeloma with B cells obtained from a mouse immunized with purified, recombinant Human c-Met (rh c-Met; Catalog#10692-H08H; NP_000236; Met 1-Thr 932). The IgG fraction of the cell culture supernatant was purified by Protein A affinity chromatography.

c-MET antibody ELISA validated

Application ELISA
Dilution 1:1000-1:2000

c-MET Antibody western blot

c-MET Antibody western blot Preparation

Produced in rabbits immunized with a synthetic peptide corresponding to the C-terminus of the Human c-Met / HGFR, and purified by antigen affinity chromatography.

c-MET Antibody western blot Validated

Application WB
Dilution 1:500-1:1000

c-MET Antibody flow cytometry

c-MET Antibody flow cytometry Preparation

This antibody was obtained from a rabbit immunized with purified, recombinant Human c-MET / HGFR (rh c-MET / HGFR; Catalog#10692-H03H; NP_000236; Met1-Thr932).

c-MET Antibody flow cytometry Validated

Application FC
Dilution 1:25-1:100

c-MET Antibody Neutralization

c-MET Antibody Neutralization Preparation

c-MET Antibody Neutralization Validated

Application Neutralization
Dilution The neutralization activity of HGFR Neutralizing Antibody is Measured by its ability to neutralize HGF induced proliferation in the U87 human glioma cell line.

c-MET antibody citations

Does smoking, age or gender affect the protein phenotype of extracellular vesicles in plasma?
Bæk, R;Varming, K;Jørgensen, MM;
Transfus. Apher. Sci.
Pharmacological induction of selective endoplasmic reticulum retention as a strategy for cancer therapy
Mahameed, M;Boukeileh, S;Obiedat, A;Darawshi, O;Dipta, P;Rimon, A;McLennan, G;Fassler, R;Reichmann, D;Karni, R;Preisinger, C;Wilhelm, T;Huber, M;Tirosh, B;
Nat Commun